651 related articles for article (PubMed ID: 11282454)
1. Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis.
Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
Cell Signal; 2001 Mar; 13(3):159-67. PubMed ID: 11282454
[TBL] [Abstract][Full Text] [Related]
2. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4.
Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
Cell Signal; 2001 Apr; 13(4):287-97. PubMed ID: 11306246
[TBL] [Abstract][Full Text] [Related]
3. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
[TBL] [Abstract][Full Text] [Related]
4. Analysis of a mutation in phosphodiesterase type 4 that alters both inhibitor activity and nucleotide selectivity.
Herman SB; Juilfs DM; Fauman EB; Juneau P; Menetski JP
Mol Pharmacol; 2000 May; 57(5):991-9. PubMed ID: 10779384
[TBL] [Abstract][Full Text] [Related]
5. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus.
Suvarna NU; O'Donnell JM
J Pharmacol Exp Ther; 2002 Jul; 302(1):249-56. PubMed ID: 12065724
[TBL] [Abstract][Full Text] [Related]
6. Implications of PDE4 structure on inhibitor selectivity across PDE families.
Ke H
Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
[TBL] [Abstract][Full Text] [Related]
7. Changes in phosphodiesterase activity in the developing rat submandibular gland.
Tanaka S; Shimooka S; Shimomura H
Arch Oral Biol; 2002 Aug; 47(8):567-76. PubMed ID: 12221013
[TBL] [Abstract][Full Text] [Related]
8. Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3.
Huston E; Lumb S; Russell A; Catterall C; Ross AH; Steele MR; Bolger GB; Perry MJ; Owens RJ; Houslay MD
Biochem J; 1997 Dec; 328 ( Pt 2)(Pt 2):549-58. PubMed ID: 9371714
[TBL] [Abstract][Full Text] [Related]
9. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells.
Verghese MW; McConnell RT; Lenhard JM; Hamacher L; Jin SL
Mol Pharmacol; 1995 Jun; 47(6):1164-71. PubMed ID: 7603456
[TBL] [Abstract][Full Text] [Related]
10. Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1).
MacKenzie SJ; Baillie GS; McPhee I; MacKenzie C; Seamons R; McSorley T; Millen J; Beard MB; van Heeke G; Houslay MD
Br J Pharmacol; 2002 Jun; 136(3):421-33. PubMed ID: 12023945
[TBL] [Abstract][Full Text] [Related]
11. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant.
Erdogan S; Houslay MD
Biochem J; 1997 Jan; 321 ( Pt 1)(Pt 1):165-75. PubMed ID: 9003416
[TBL] [Abstract][Full Text] [Related]
12. Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse.
Cherry JA; Thompson BE; Pho V
Biochim Biophys Acta; 2001 Mar; 1518(1-2):27-35. PubMed ID: 11267656
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a novel cAMP-binding, cAMP-specific cyclic nucleotide phosphodiesterase (TcrPDEB1) from Trypanosoma cruzi.
Díaz-Benjumea R; Laxman S; Hinds TR; Beavo JA; Rascón A
Biochem J; 2006 Oct; 399(2):305-14. PubMed ID: 16776650
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the structure of a low Km, rolipram-sensitive cAMP phosphodiesterase. Mapping of the catalytic domain.
Jin SL; Swinnen JV; Conti M
J Biol Chem; 1992 Sep; 267(26):18929-39. PubMed ID: 1326538
[TBL] [Abstract][Full Text] [Related]
15. Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process.
Terry R; Cheung YF; Praestegaard M; Baillie GS; Huston E; Gall I; Adams DR; Houslay MD
Cell Signal; 2003 Oct; 15(10):955-71. PubMed ID: 12873709
[TBL] [Abstract][Full Text] [Related]
16. Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4).
Thompson WJ; Ashikaga T; Kelly JJ; Liu L; Zhu B; Vemavarapu L; Strada SJ
Biochem Pharmacol; 2002 Feb; 63(4):797-807. PubMed ID: 11992650
[TBL] [Abstract][Full Text] [Related]
17. Functional plasticity of cyclic AMP hydrolysis in rat adenohypophysial corticotroph cells.
Ang KL; Antoni FA
Cell Signal; 2002 May; 14(5):445-52. PubMed ID: 11882389
[TBL] [Abstract][Full Text] [Related]
18. Identification of overlapping but distinct cAMP and cGMP interaction sites with cyclic nucleotide phosphodiesterase 3A by site-directed mutagenesis and molecular modeling based on crystalline PDE4B.
Zhang W; Ke H; Tretiakova AP; Jameson B; Colman RW
Protein Sci; 2001 Aug; 10(8):1481-9. PubMed ID: 11468344
[TBL] [Abstract][Full Text] [Related]
19. Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium.
Hambleton R; Krall J; Tikishvili E; Honeggar M; Ahmad F; Manganiello VC; Movsesian MA
J Biol Chem; 2005 Nov; 280(47):39168-74. PubMed ID: 16172121
[TBL] [Abstract][Full Text] [Related]
20. Molecular docking of competitive phosphodiesterase inhibitors.
Dym O; Xenarios I; Ke H; Colicelli J
Mol Pharmacol; 2002 Jan; 61(1):20-5. PubMed ID: 11752202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
